Opioid-Related Infectious Endocarditis Increasing In Young Women, Whites

Share this content:
The proportion of infective endocarditis hospitalizations caused by injection drug use increased from 2000 to 2013.
The proportion of infective endocarditis hospitalizations caused by injection drug use increased from 2000 to 2013.

A study conducted by researchers at Tufts Medical Center and Tufts University School of Medicine and recently published in Open Forum Infectious Diseases indicates a shifting in the demographics of hospitalizations for infective endocarditis.1 In particular, scientists observed a significant increase in those aged 15-34 — particularly women — and in whites.

Because infectious endocarditis is often related to injection drug use (IDU), its higher prevalence in particular population groups points to demographic shifts in those swept up in the opioid epidemic.

“I decided to do this analysis because in the hospital I noticed increased numbers of young people admitted with injection-drug related endocarditis. I discussed this with other physicians in Boston who were seeing the same change in IDU-related complications to include younger patients,” Alysse G. Wurcel, MD, MS, an infectious diseases physician at Tufts Medical Center, told Clinical Pain Advisor.

“There has [also] been an increase in hepatitis C virus (HCV) in younger populations, which also guided our analysis, since the major method of transmission is injection drug use,” she added.

In order to determine whether infective endocarditis cases were paralleling drug use, the researchers examined data from the Nationwide Inpatient Samples (NIS) gathered between 2000 and 2013. NIS is the largest public database for inpatient hospital care in the US.2

Infective endocarditis cases related to drug use and in patients with hepatitis C, but not those caused by congenital defects were included in the study.

Data analysis indicated the following trends:

  • The proportion of infective endocarditis hospitalizations caused by injection drug use increased from 7% in 2000 to 12.1% in 2013.
  • While infective endocarditis due to injection drug use steadily decreased in middle-aged adults (ages 35–54) from 67.2% in 2000 to 39.9% to 2013 (P < .001), it steadily increased in young adults (ages 15-34) from 2000 to 2013, with a sharp rise from 27.7%  in 2008 to 42.0% in 2013 (P < .001).
  • Whites represented 40.2% of infective endocarditis cases due to drug injection in 2000, and increased to 68.9% of cases in 2013 (P < .001). The proportion of younger white patients also rose from 57.0% in 2000 to 80.3% in 2013 (P < .001).
  • While women only represented 40.9% of infective endocarditis cases overall, the proportion of women in the 15-34 age group was 53%.

“One of the most severe consequences of injection drug use — endocarditis — has a changing epidemiology with increasing frequency in young patients (under 34), whites and females,” Dr Wurcel said.

The researchers noted that this increase in infective endocarditis in young adults may indicate a stable risk in a growing population of drug users or the appearance of certain behaviors within the younger subgroup of drug users that increase risks of infective endocarditis.

Clinical Implications

“These findings are not surprising to me, but may be surprising to people who do not work as inpatient clinicians or with people with addiction,” Dr Wurcel noted. “When clinicians are evaluating patients with symptoms concerning for endocarditis, they should make sure to question the patients about drug use, even if the patient does not have the stereotypical appearance of someone who uses drugs.”

Prevention and Future Research

Dr Wurcel noted that even though harm reduction programs such as opioid replacement treatment or needle exchanges may be expensive, money may potentially be saved by preventing complications of injection drug use.

“Endocarditis is a costly and severe complication of injection drug use, and it may be worth investing more money in harm reduction strategies like opiate replacement programs and needle exchanges,” she said. “We need more research in prospective clinical studies to see which interventions work [and to] get a better idea of how much money could be saved (and lives saved) through their implementation.”

Dr Wurcel also stated that further research is needed to study methods of preventing infective endocarditis in drug users.

 

Follow @ClinicalPainAdv

References

  1. Wurcel AG, Anderson JE, Chui KKH, et al. Increasing Infectious Endocarditis Admissions Among Young People Who Inject Drugs. Open Forum Infect Dis. 2016;3(3). doi:10.1093/ofid/ofw157.
  2. HCUP Databases. Healthcare Cost and Utilization Project (HCUP). 2000-2013. Agency for Healthcare Research and Quality, Rockville, MD. Available at: http://www.hcup-us.ahrq.gov/db/nation/nis/nisdbdocumentation.jsp. Accessed September 14, 2016.
You must be a registered member of Clinical Pain Advisor to post a comment.